Xiong Lisa Y, Wood Alexander Madeline, Wong Yuen Yan, Wu Che-Yuan, Ruthirakuhan Myuri, Edwards Jodi D, Lanctôt Krista L, Black Sandra E, Rabin Jennifer S, Cogo-Moreira Hugo, Swardfager Walter
Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
Mol Psychiatry. 2025 Feb;30(2):450-460. doi: 10.1038/s41380-024-02685-4. Epub 2024 Aug 5.
In 2020, the Lancet Commission identified 12 modifiable factors that increase population-level dementia risk. It is unclear if these risk factors co-occur among individuals in a clinically meaningful way. Using latent class analysis, we identified profiles of modifiable dementia risk factors in dementia-free adults aged 60-64 years from the UK Biobank. We then estimated associations between these profiles with incident dementia, cognition, and neuroimaging outcomes, and explored the differences across profiles in the effects of a polygenic risk score for Alzheimer's disease on outcomes. In 55,333 males and 63,063 females, three sex-specific latent profiles were identified: cardiometabolic risk, substance use-related risk, and low risk. The cardiometabolic risk profile in both males and females was associated with greater incidence of all-cause dementia (male: OR [95% CI] = 2.33 [2.03, 2.66]; female: OR [95% CI] = 1.44 [1.24, 1.68]), poorer cognitive performance, greater brain atrophy, and greater white matter hyperintensity volume compared to the low risk profile. The substance use-related risk profile in males was associated with poorer cognitive performance and greater white matter hyperintensities compared to the low risk profile, but no difference in all-cause dementia incidence was observed (OR [95% CI] = 1.00 [0.95, 1.06]). In females, the substance use-related risk profile demonstrated increased dementia incidence (OR [95% CI] = 1.58 [1.57, 1.58]) and greater brain atrophy but smaller white matter hyperintensity volume compared to the low risk profile. The polygenic risk score had larger effects among females, and differentially influenced outcomes across profiles; for instance, there were larger effects of the polygenic risk score on atrophy in the cardiometabolic profile vs. the low risk profile among males, and larger effects of the polygenic risk score on loss of white matter integrity in the cardiometabolic profile vs. the low risk profile among females. These results reveal three modifiable dementia risk profiles, their unique cognitive/neuroimaging outcomes, and their interactions with genetic risk for Alzheimer's disease. These differences highlight the need to consider population heterogeneity in risk prediction tools and in planning personalized prevention strategies.
2020年,《柳叶刀》委员会确定了12个可改变的因素,这些因素会增加人群层面患痴呆症的风险。目前尚不清楚这些风险因素在个体中是否以具有临床意义的方式同时出现。我们使用潜在类别分析,从英国生物银行中确定了60 - 64岁无痴呆症成年人中可改变的痴呆症风险因素概况。然后,我们估计了这些概况与痴呆症发病率、认知和神经影像学结果之间的关联,并探讨了阿尔茨海默病多基因风险评分对结果影响在不同概况之间的差异。在55333名男性和63063名女性中,确定了三种特定性别的潜在概况:心血管代谢风险、物质使用相关风险和低风险。与低风险概况相比,男性和女性的心血管代谢风险概况均与全因痴呆症发病率更高(男性:OR[95%CI]=2.33[2.03, 2.66];女性:OR[95%CI]=1.44[1.24, 1.68])、认知表现更差、脑萎缩更严重以及白质高信号体积更大有关。与低风险概况相比,男性的物质使用相关风险概况与认知表现更差和白质高信号更强有关,但在全因痴呆症发病率方面未观察到差异(OR[95%CI]=1.00[0.95, 1.06])。在女性中,与低风险概况相比,物质使用相关风险概况显示痴呆症发病率增加(OR[95%CI]=1.58[1.57, 1.58])且脑萎缩更严重,但白质高信号体积更小。多基因风险评分在女性中的影响更大,并且对不同概况的结果有不同影响;例如,多基因风险评分对男性心血管代谢概况与低风险概况之间的萎缩影响更大,对女性心血管代谢概况与低风险概况之间的白质完整性丧失影响更大。这些结果揭示了三种可改变的痴呆症风险概况、它们独特的认知/神经影像学结果以及它们与阿尔茨海默病遗传风险的相互作用。这些差异凸显了在风险预测工具和规划个性化预防策略时考虑人群异质性的必要性。